L-DOS 47

Drug Profile

L-DOS 47

Alternative Names: L-DOS-47

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Urease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 27 Sep 2017 US FDA approves amendment in the protocol of the phase I LDOS001 trial
  • 27 Sep 2017 Interim efficacy data from the phase LDOS001 trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Late-stage disease) released by Helix Biopharma
  • 01 Sep 2017 Helix Biopharma has patent protection for DOS47 technology (Helix BioPharma pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top